Thelansis

Metastatic Pancreatic Adenocarcinoma (mPDAC) Emerging Therapy and TPP Insights Thelansis’s “Metastatic Pancreatic Adenocarcinoma (mPDAC) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Metastatic Pancreatic Adenocarcinoma (mPDAC) Overview Pancreatic Cancer (PC) is a lethal malignancy, with its prevalence, although relatively low, steadily increasing each year. Metastatic PC, categorized as late-stage (stage IV), represents the most advanced form of the disease, boasting an even higher fatality rate compared to other stages. Notably, patients affected by PC typically lack specific clinical manifestations. The major signaling pathways in metastatic pancreatic cancer include Epithelial-Mesenchymal Transition (EMT) and NF-κB ...

Metastatic Pancreatic Adenocarcinoma (mPDAC) Emerging Therapy and TPP Insights Thelansis’s “Metastatic Pancreatic Adenocarcinoma (mPDAC) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Key business questions answered: Detailed emerging competitive landscape Pipeline analysis Target patients for emerging therapies Key companies Key mechanism of actions Launch date estimates, etc. Clinical trial landscape analysis Target patient segments Trial endpoints Trial design Recruitment criteria, etc. Unmet Needs and Opportunities Performance of key current therapies Top areas of unmet needs Opportunity sizing for key unmet ...